-
公开(公告)号：US09631004B2
公开(公告)日：2017-04-25
申请号：US15215329
申请日：2016-07-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20220185856A1
公开(公告)日：2022-06-16
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US11344639B2
公开(公告)日：2022-05-31
申请号：US16305284
申请日：2017-05-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen , David K. Leung
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US10406251B2
公开(公告)日：2019-09-10
申请号：US15529260
申请日：2015-11-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria N. Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen
IPC: A61K51/08 , C07K14/78 , G01N33/60 , G01N33/68 , G01N33/574
Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US10377806B2
公开(公告)日：2019-08-13
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
Patent Agency Ranking
公开(公告)号：US10189883B2
公开(公告)日：2019-01-29
申请号：US15460917
申请日：2017-03-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US12194110B2
公开(公告)日：2025-01-14
申请号：US17483393
申请日：2021-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria N. Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie Lafont , Daniel Cohen
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US11173219B2
公开(公告)日：2021-11-16
申请号：US16520965
申请日：2019-07-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , David Donnelly , Dasa Lipovsek , Jochem Gokemeijer , Maria Jure-Kunkel , David Fabrizio , Martin C. Wright , Douglas Dischino , Samuel J. Bonacorsi, Jr. , Ralph Adam Smith , Virginie LaFont , Daniel Cohen
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US20190382460A1
公开(公告)日：2019-12-19
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20180243375A1
公开(公告)日：2018-08-30
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
IPC: A61K38/18
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K45/06 , A61K47/60 , A61K47/64 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.033 seconds)
